IMODIUM® launches new Gut2KnowTM app: diarrhoea sufferers can now boost their gut health with personalised data

1 February 2024: Gut2Know^TM by IMODIUM^® is a new personal gut health app, which empowers diarrhoea sufferers to boost their gut knowledge and track and identify triggers for their symptoms, such as stress or diet.

The free new app, which is available across the Apple App Store and Google Play in the UK, launches as 64% of diarrhoea sufferers* say they want more support to better understand their gut health¹.

The holistic gut health app allows users to track food, mood, and symptoms to identify their triggers, and ultimately build new healthy habits tailored to their individual needs. This includes learning modules to help people understand the digestive system, diarrhoea as a condition, and how gut health can be affected by aspects of everyday life – helping users make informed decisions and lifestyle changes.

Gut2Know^TM was carefully developed, using key insights from pharmacists, gastro-intestinal doctors, and nutritionists, in recognition of the need to not only treat the immediate symptoms of diarrhoea, but also the underlying mechanisms behind poor gut health.

Those living with digestive health issues say that too often they suffer their symptoms in silence². Providing an additional option for this group, initial piloting of Gut2Know^TM found that overall the app felt easy to use and intuitive³. Overall, piloting feedback also found it felt like the app tangibly made a difference to people during the three week trial⁴. All healthcare professionals involved in early piloting said they saw a relevant and supportive role for the app within their practice and interactions with patients⁵.

A poll commissioned by the IMODIUM^® brand found that 70% of people recognize that gut health is central to wellbeing⁶. And it is important that people truly understand the mechanisms behind the gut health issues they may face on a regular basis. Medical advice is still crucial in dealing with underlying health conditions and triggers such as stress, anxiety, mood, or food intolerances. However, Gut2Know^TM helps users to begin to identify triggers in their daily routines, which can then be shared with healthcare professionals to help further manage their symptoms and any underlying conditions.

Gut2Know^TM uses AI to analyse input on symptoms and food tracking to identify potential triggers. Through in-app learning modules it offers personalised and practical ‘things to try’ to help users build better gut habits, as well as providing regular health questionnaires to track positive changes over time. The app also provides ongoing encouragement to keep up progress through regular prompts and nudges. As people input more information on their symptoms and triggers, the app is able to provide more tailored analysis and richer insights. 

Kenvue, the makers of IMODIUM^®, has launched the app in the UK as the latest example of how the consumer health company’s brands leverage its expertise and marry science and technology to create innovative health products for consumers. 

Angeliki Kazantzidi, Head of Marketing for Kenvue in Northern Europe**, said: “We know how disruptive diarrhoea symptoms can be and hope that our new Gut2Know^TM app by IMODIUM^® gives people the everyday self-care insights they need to better understand their triggers, and make simple changes to help return to their regular routines. Gut health symptoms are too often stigmatised, which is why we want to demystify these health issues and help people find a healthy balance for their digestive system.”

An upset stomach and diarrhoea can be incredibly disruptive to people’s daily lives and routines, but symptoms can be effectively managed through a combination of professional medical advice, lifestyle changes and over the counter medication. Alongside the IMODIUM^® range, which can relieve diarrhoea symptoms within one hour, Gut2Know^TM offers a source of support and fuller consumer experience, beyond the product, through digital personalisation.

-ENDS-

NOTES TO EDITORS

*defined as adults who suffered from diahrhoea at least once in the last 12 months.

**Kenvue (Johnson & Johnson Ltd)

ABOUT IMODIUM^®

IMODIUM^® exists to calm the chaos of diarrhoea, and has been doing just that for over 50 years. IMODIUM^® products provide diarrhoea relief within an hour by gently slowing down gut movement to its natural pace, allowing for better absorption of water and essential nutrients. IMODIUM^® Dual Action also helps to alleviate symptoms that often accompany diarrhoea, including cramps, bloating and wind. IMODIUM^®: Calm the Chaos of diarrhoea .

PRODUCT INFORMATION

IMODIUM^® Original capsules, IMODIUM^® Instants, and IMODIUM^® IBS Relief Capsules contain loperamide hydrochloride. For acute diarrhoea (aged 12+) and for medically diagnosed IBS diarrhoea (aged 18+). IMODIUM^® Dual Action Tablets. For acute diarrhoea and its gas related symptoms (aged 12+). Always read the label.

Please note that the Gut2Know^TM app is not a substitute for professional medical advice. If you experience severe, recurrent, or persistent diarrhoea or have any medical conditions please consult a doctor for further guidance.

PRESS CONTACT DETAILS 

Kaizo PR

0203 176 4700

kenvue@kaizo.co.uk

REFERENCES:

1. IMODIUM^® OnePoll Survey of 2,000 UK adults, April 2023.
2. IMODIUM^® App Testing Consumer Debrief, January 2023 (page 4).
3. IMODIUM^® App Testing Consumer Debrief, January 2023 (page 9).
4. Kenvue Project Zen Validation Opportunity Debrief, November 2023 (page 3). 
5. IMODIUM^® App Testing HCP Debrief, March 2023 (page 4).
6. Kenvue Digestive Health Diarrhoea U&A, March 2021.

CAUTIONS CONCERNING FORWARD-LOOKING STATEMENTS

This media alert contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding a new Gut2Know^TM mobile app by the IMODIUM^® brand. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue Inc. (“Kenvue”) and its affiliates. A list and descriptions of these risks, uncertainties and other factors can be found in Kenvue’s filings with the Securities and Exchange Commission available at www.kenvue.com or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.